) The DNA Sequencing and Analysis Core is now in its 4th year of highly successful operation. Initiated as a fledging operation after the inception of the CU Cancer Center, the Core has grown remarkably with now 112 user groups, of which most are Cancer Center members. In addition to performing DNA sequencing reactions, Core services include preparation of various DNA templates and assisting customers with all technical aspects of DNA sequencing and analysis. The Core also prepares high-density filter arrays using customer prepared libraries. In addition to service functions, Core personnel reported improvements in basic DNA sequencing chemistry that permit longer, more accurate read-lengths and improved mutation detection. To facilitate research efforts of the CU Hereditary Cancer Clinic, the Core now offers screening for the BRCA1/2 185delAG, 5382insC and 6174delT mutations. Especially as a consequence of the Genome Project, the demand for DNA sequencing will continue to expand significantly. During the next period of support, the Core intends to continue its state-of-the-art services to Cancer Center members. Research-based mutation/polymorphism screening is also likely to expand. Over the past 4 years samples sequenced have increased from 1501 to 9410 (526%) and charge back fees have increased from $43,095 to $187,136 (334%). Because of the large increase we have been able to reduce fees which has led to continued increases in core usage. The core has been used by members of 9 of the 10 Cancer Center programs. The core will move to the Fitzsimons campus with the Cancer Center during the next grant cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-15S1
Application #
6664430
Study Section
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Petersen, Dennis R; Orlicky, David J; Roede, James R et al. (2018) Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. Exp Mol Pathol 105:32-36
Couts, Kasey L; Bemis, Judson; Turner, Jacqueline A et al. (2018) ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther 17:222-231
Nicholson, Andrew G; Torkko, Kathleen; Viola, Patrizia et al. (2018) Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 13:205-217
Coleman, Carrie B; Lang, Julie; Sweet, Lydia A et al. (2018) Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol 92:
Thompson, Scott B; Wigton, Eric J; Krovi, Sai Harsha et al. (2018) The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo. Front Oncol 8:389
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Sang, Allison; Danhorn, Thomas; Peterson, Jacob N et al. (2018) Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun 9:3973
Greaves, Sarah A; Peterson, Jacob N; Torres, Raul M et al. (2018) Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance. Front Immunol 9:707
Flannery, Patrick C; DeSisto, John A; Amani, Vladimir et al. (2018) Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39:455-464
Elder, Alan M; Tamburini, Beth A J; Crump, Lyndsey S et al. (2018) Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling during Postpartum Mammary Gland Involution and in Breast Cancer. Cancer Res 78:6473-6485

Showing the most recent 10 out of 1634 publications